MiniMed Q4 net sales $837M (+16% as reported); FY27 organic growth guidance ~10%

MiniMed Group, Inc.

Q4 net sales $837M (+15.6% as reported, +8.7% organic); International $599M (+22.4% as reported, +12.2% organic).
Full FY26 net sales $3.102B (+14.2% as reported, +8.0% organic); first annual revenue >$3B.
Worldwide New Pumps Sold ~42,000 in Q4 (+7.4% QoQ); FY26 total ~145,000 flat YoY; CGM attachment rate 66% (+700 bps YoY).
FY27 guidance: organic revenue growth ~10% (including ~1.0-1.5% extra week benefit); adjusted EBITDA margin ~16%.
Product milestones: MiniMed Flex FDA clearance, MiniMed Go US launch, extension of Abbott partnership for dual glucose-ketone sensors.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MiniMed Group, Inc. reported financial results for fourth quarter and full fiscal year ended April 24, 2026.

Period: fourth quarter and full fiscal year ended April 24, 2026
Result: reported results

Exact text from the filing

On June 3, 2026, MiniMed Group, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results and related information for its fourth quarter and full fiscal year 2026.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

MiniMed Group, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-040036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.